229 related articles for article (PubMed ID: 11258670)
1. Kinins, receptors, kininases and inhibitors--where did they lead us?
Erdös EG; Marcic BM
Biol Chem; 2001 Jan; 382(1):43-7. PubMed ID: 11258670
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibitor potentiation of bradykinin-induced venoconstriction.
Hecker M; Blaukat A; Bara AT; Müller-Esterl W; Busse R
Br J Pharmacol; 1997 Aug; 121(7):1475-81. PubMed ID: 9257930
[TBL] [Abstract][Full Text] [Related]
3. Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors.
Chen Z; Tan F; Erdös EG; Deddish PA
Hypertension; 2005 Dec; 46(6):1368-73. PubMed ID: 16246972
[TBL] [Abstract][Full Text] [Related]
4. [ACE inhibitors--activators of kinin receptors].
Kugaevskaia EV; Eliseeva IuE
Biomed Khim; 2011; 57(3):282-99. PubMed ID: 21863742
[TBL] [Abstract][Full Text] [Related]
5. Kinin-related effects of angiotensin-converting enzyme inhibition.
Bönner G
Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells.
Kohlstedt K; Brandes RP; Müller-Esterl W; Busse R; Fleming I
Circ Res; 2004 Jan; 94(1):60-7. PubMed ID: 14615289
[TBL] [Abstract][Full Text] [Related]
7. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
[TBL] [Abstract][Full Text] [Related]
8. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands.
Ignjatovic T; Stanisavljevic S; Brovkovych V; Skidgel RA; Erdös EG
Mol Pharmacol; 2004 Nov; 66(5):1310-6. PubMed ID: 15304551
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE.
Ceconi C; Francolini G; Olivares A; Comini L; Bachetti T; Ferrari R
Eur J Pharmacol; 2007 Dec; 577(1-3):1-6. PubMed ID: 17716647
[TBL] [Abstract][Full Text] [Related]
10. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
11. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
Mukae S; Itoh S; Aoki S; Iwata T; Nishio K; Sato R; Katagiri T
J Hum Hypertens; 2002 Dec; 16(12):857-63. PubMed ID: 12522467
[TBL] [Abstract][Full Text] [Related]
12. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition.
Henriksen EJ; Jacob S
J Cell Physiol; 2003 Jul; 196(1):171-9. PubMed ID: 12767053
[TBL] [Abstract][Full Text] [Related]
13. Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors.
Marcic B; Deddish PA; Skidgel RA; Erdös EG; Minshall RD; Tan F
J Biol Chem; 2000 May; 275(21):16110-8. PubMed ID: 10748135
[TBL] [Abstract][Full Text] [Related]
14. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
15. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
16. Signaling via the angiotensin-converting enzyme results in the phosphorylation of the nonmuscle myosin heavy chain IIA.
Kohlstedt K; Kellner R; Busse R; Fleming I
Mol Pharmacol; 2006 Jan; 69(1):19-26. PubMed ID: 16186248
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells.
Minshall RD; Tan F; Nakamura F; Rabito SF; Becker RP; Marcic B; Erdös EG
Circ Res; 1997 Nov; 81(5):848-56. PubMed ID: 9351459
[TBL] [Abstract][Full Text] [Related]
18. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.
Deddish PA; Marcic B; Jackman HL; Wang HZ; Skidgel RA; Erdös EG
Hypertension; 1998 Apr; 31(4):912-7. PubMed ID: 9535414
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin.
Marcic BM; Erdös EG
J Pharmacol Exp Ther; 2000 Aug; 294(2):605-12. PubMed ID: 10900238
[TBL] [Abstract][Full Text] [Related]
20. Contributions of various rat plasma peptidases to kinin hydrolysis.
Ishida H; Scicli AG; Carretero OA
J Pharmacol Exp Ther; 1989 Dec; 251(3):817-20. PubMed ID: 2557417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
